The Black Technology Era of Xueba

"Seattle Times": Pangu's clinical experiment seriously violated medical regulations. It took less than half a year from the appearance of their technology to the final clinical treatment. This not only violated the international clinical experiment rules on the treatment of malignant tumors, but also violated the Xia Guo's own rules for clinical experiments. We have reason to suspect that Pangu's clinical experiments are just simple procedures, and we have reasons to suspect that Pangu's technology comes from the United States.

"New York Times": The New York court accepted Bristol-Myers Squibb's infringement case concerning Pangu Technology's gene expression inhibitory therapy. Bristol-Myers Squibb Company has provided sufficient evidence. If Pangu Technology does not sue, the court will try in absentia. In addition, Bristol-Myers Squibb also appealed the case to more than 20 international intellectual property organizations, and requested the relevant departments of Xia Guo to face up to the demands of Bristol-Myers Squibb Company and stop the treatment qualification of Pangu Technology's related technologies.

After the news of The New York Times came out, many Western media rushed to report it.

Several well-known medical institutes, including Stanford University's Institute of Molecular Medicine, the Mayo Clinic, and the Moffett Cancer Center and Research Institute, have followed the progress of the matter.

They expressed doubts after Pangu's paper came out, and they even doubted the authenticity of the "Gene Expression" paper published in the "Cell" journal.

At the same time, the U.S. FDA also officially issued a notice of investigation to Pangu Technology. The reason for FDA’s suspicion of Pangu Technology is that the patient’s physical indicators before and after treatment in Pangu Technology’s paper, and the treatment methods are similar to those after nivolumab treatment. .

Gao Siqi came to Xiao Ming's office with the FDA's investigation notice and said, "Americans are going crazy!"

Qian Yi, who was talking with Xiao Ming, looked at the investigation notice and said, "What are they thinking? Pangu Technology does not have any business in the United States. Can a department in the United States investigate Xia Guo's company?"

"Bristol-Myers Squibb's nivolumab has been banned worldwide, and the FDA has asked us to stop suppressing gene therapy," said Gao Siqi.

Qian Yi asked strangely: "Nivolumab has stopped selling globally? Isn't Bristol-Myers Squibb a serious loss?"

Xiao Ming knew what Gao Siqi was trying to convey. He said: "The FDA and more than 20 intellectual property organizations around the world should investigate us not only by Bristol-Myers Squibb, but by the entire American medical community. Bristol-Myers Squibb has lost an The sale of nivolumab, which has been on the market soon, in exchange for Xia Guo losing a treatment method that has changed the global medical industry, this transaction is quite cost-effective!"

Gao Siqi also added: "Now I completely understand the calculations of American companies. Bristol-Myers Squibb Company has many cancer-targeted drugs, even if nivolumab is no longer sold for the time being, there are still many alternative cancer-targeted drugs, which are very important to their profits. There is almost no loss, the only loss is the patient's chance of survival. Even if those cancer patients can't buy nivolumab, they will buy other drugs from Bristol-Myers Squibb, but what Pangu Technology and the whole country have lost is inhibiting the development of gene therapy. Chance."

Qian Yi asked: "These pharmaceutical companies and medical departments in the United States are so bloody? Don't they care about the survival rate of patients?"

Xiao Ming smiled and said: "Blood? Which pharmaceutical company did not rely on blood to make a fortune? In the United States, cancer only has life expectancy, and there is no 100% successful treatment. As long as the interests are not damaged, early death and late death do not seem to these pharmaceutical companies. What a difference."

Gao Siqi said: "According to the agreements of various intellectual property organizations, the relevant departments of Xia Guo should respond to them. Anyway, our Pangu Technology will not make any response. I am afraid of fighting with the United States and say no for a few years. clear."

"The news is here." Qian Yi said while swiping her phone.

On Weibo, Xia Guo’s media have spoken out against the FDA’s notice. In addition to stern refutation, they also accused the US law of not being able to govern Xia Guo’s companies.

Qian Yi handed the phone to Xiao Ming.

In addition to the refutation of the FDA notice by Xia Guo Media,

Many netizens are also speaking for Pangu Technology.

"Americans are disgusting! How can I use American laws to demand Xia Guo's company?"

"We don't use the operating system of the United States, why are we still saying that we violate intellectual property rights?"

"Just can't see us, okay?"

"It must be said that we are infringing intellectual property rights! Imported targeted drugs cost tens of thousands of dollars a month, and our technology can cure all three or four million. Is there any way for these American pharmaceutical companies to survive?"

The Affiliated Hospital of Jiangcheng University also spoke out for Pangu Technology. In the announcement of the affiliated hospital, more than a dozen oncology experts said: "Pangu Technology has independent intellectual property rights, and it is a new generation of nausea tumors that is advanced in targeted therapy. therapy. Jiangcheng University will not stop using this technology to treat patients.”

After reading the news, Xiao Ming said: "Pangu Technology will solve the problem of Pangu Technology itself, and we have to learn to deal with Westerners from this matter."

Xiao Ming arranged a task for Gao Siqi and said, "Don't worry about anything, and proceed as planned. We have no business in the United States, and we will not be afraid of his investigation and trial. Also, if Xia Guo really accepts the conditions of the United States, suppressing gene therapy is prohibited. If it is used in the medical field of Xiaguo, then I think Pangu Group can also move."

What Xiao Ming said was very serious. This incident was a test for Pangu Technology, and it was also a test for Xia Guo's technical confidence.

However, with Xiao Ming's instructions, Gao Siqi was more able to carry out work boldly.

The first is to increase the production capacity of inhibitors, and the second is to cooperate with the Affiliated Hospital of Jiangcheng University to expand the admission of patients.

Xiao Ming also made an agreement with the Affiliated Hospital of Jiangda University. After the Affiliated Hospital of Jiangda University is full of patients, it will spread out with the Affiliated Hospital of Jiangda University as the center, and send technicians to other tertiary hospitals, so that patients from all over the country will be at their doorsteps. can be treated.

The Affiliated Hospital of Jiangcheng University also stated that it will actively communicate with the higher authorities to strive not to implement the technical temporary ban.

Many patients are very flustered after seeing foreign media reports and various news on the Internet. If gene expression inhibition therapy is really banned, what will the patients do?

Many people leave messages under Pangu Technology, asking for the latest news.

"Why do Americans manage our patients in Xia Guo!"

"Don't ban it! I just registered for my father!"

"If joining the International Intellectual Property Organization has such an impact on the Summer Conference, why should we join?"

For the patients' questions, Pangu Technology responded uniformly: "We will not give up any patient."

Genius for a second to remember the address of this site: . Mobile version reading website: